The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

This study is a prospective, randomized, single-center randomized controlled clinical trial to investigate the safety and efficacy of ondansetron in reducing the toxicity associated with immune checkpoint inhibitor treatment. This study plans to enroll 134 patients with hepatocellular carcinoma who are scheduled to receive standard ICI treatment. This study will adopt the 2023 CSCO Guidelines for the Management of Immune checkpoint inhibitor-related toxicity as the main assessment criterion, and take the incidence and severity of irAEs as the main observation indicators to evaluate the effecti

Trial Details

NCT ID
NCT07381634
Phase
PHASE2
Sponsor
First Affiliated Hospital of Wenzhou Medical University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ondansetron
Locations (sample)
  • Wenzhou, Zhejiang, China|27.99942,120.66682

Key Eligibility Criteria

  • Age: 18 to 80 years old, both male and female are acceptable.
  • The imaging or pathological diagnosis is hepatocellular carcinoma;
  • It is planned to carry out standard treatment for liver cancer, specifically including lenvatinib + tislelizumab or lenvatinib + pembrolizumab or a…
  • ECOG score: 0 to 2 points;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →